{
  "report_rows": [
    {
      "kpi": "Adj. EPS (Q1 FY2027)",
      "prediction": "BEAT",
      "answer": "pred ~$9.85 vs. cons $9.551",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Oncology & Multispecialty Adj. Seg. OP (Q1 FY2027)",
      "prediction": "IN-LINE",
      "answer": "pred ~$375M vs. cons $375.3M",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "RxTS Adj. Seg. OP (Q1 FY2027)",
      "prediction": "BEAT",
      "answer": "pred ~$310M vs. cons $300.9M",
      "confidence": "MEDIUM"
    }
  ],
  "guide_rows": [
    {
      "kpi": "Adj. EPS FY2027 (full year)",
      "prediction": "UNCHANGED",
      "answer": "guide maintained $43.80-$44.60 vs. cons $44.253",
      "confidence": "HIGH"
    },
    {
      "kpi": "GLP-1 trajectory (qualitative, Q1 FY2027)",
      "prediction": "UNCHANGED",
      "answer": "sequential volume recovery commentary; continued growth reaffirmed",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Med-Surg separation (qualitative, FY2027)",
      "prediction": "UNCHANGED",
      "answer": "progress update, no acceleration; IPO timeline TBD",
      "confidence": "HIGH"
    }
  ],
  "day1_residual_pct": -1.5,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": -3.0,
  "day5_path": "FADE",
  "day5_rationale": "FADE \u2014 implicit out-quarter EPS cut pulls Q2 estimates lower post-print; sell-side models off the maintained FY guide math",
  "day5_confidence": "MEDIUM"
}